Efficacy and safety of secukinumab in the treatment of chronic plaque psoriasis: A 52-weeks follow up study
Keywords:
Psoriasis, secukinumab, PASIAbstract
Background Psoriasis is a chronic inflammatory skin disease and other multiple chronic conditions are observed with it, including depression, cardio-metabolic disorders and diminished quality of life. Interleukin (IL)-17A  has a fundamental role in the pathogenesis of psoriasis. Secukinumab is a monoclonal anti-IL-17A antibody and it is recommended to be used in plaque psoriasis of moderate to severe intensity.  Objective To determine efficacy and safety of secukinumab in the treatment of chronic plaque psoriasis.  Methods Twelve patients with chronic plaque psoriasis, fulfilling the inclusion and exclusion criteria, were enlisted in this study. Secukinumab (300 mg) subcutaneously at weekly intervals was given to patients  for two consecutive weeks followed by 150 mg dose at weekly intervals for three weeks and then a dose of 150 mg at monthly intervals until week 24. Each patient was followed up for 52 weeks. Primary end points for establishing the efficacy of the treatment was achievement of PASI 75 and DLQI score of 0-1, at week 12. Safety of secukinumab was assessed by observing any side effects in the patients on each follow up visit.  Results Both primary efficacy end points were achieved in our study. PASI 75 was attained in 11 (91.7%) patients at week 12. DLQI score of 0-1 was observed in 11 (91.7%) patients at week 12. There were no significant side effects  seen in any of the patients.  Conclusion Secukinumab showed excellent efficacy in the treatment of moderate to severe chronic plaque psoriasis with a very good safety profile. ÂReferences
Langley RG, Elewski BE, Lebwohl M, Reich K, Griffiths C, Papp K, et al. Secukinumab in plaque psoriasis – results of two phase 3 trials: for the ERASURE and FIXTURE study groups. N Engl J Med. 2014;371(4):326-38.
Griffiths CE, Barker JN. Pathogenesis and clinical features of psoriasis. Lancet. 2007:370;263-71.
Raharja A, Mahil SK, Barker JN. Psoriasis: a brief overview. Clin Med (Lond). 2021;21(3):170-73.
Jacobson CC, Kumar S, Kimball AB. Latitude and psoriasis prevalence. J Am Acad Dermatol. 2011;65(4):870-73.
Park H, Li Z, Yang XO, Chang SH, Nurieva R, Wang YH, et al. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol. 2005;6(11):1133-41.
Harrington LE, Hatton RD, Mangan PR, Turner H, Murphy TL, Murphy KM, et al. Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol. 2005;6(11):1123-32.
Girolomoni G, Mrowietz U, Paul C. Psoriasis: rationale for targeting interleukin-17. Br J Dermatol. 2012;167(4):717-24.
Ejaz A, Suhail M, Iftikhar A. Psoriasis in Pakistani population: Associations, comorbidities, and hematological profile. J Pad Assoc Dermatol. 2013;23(1):42-46.
Lu Y, Chen H, Nikamo P, Low HQ, Helms C, Seielstad M, et al. Association of cardiovascular and metabolic disease genes with psoriasis. J Invest Dermatol. 2013;133(3):836-39.
Rebora A. Conventional therapies for psoriasis. Reumatismo. 2007;59(1):77-80.
Rich SJ, Bello-Quintero CE. Advancements in the treatment of psoriasis: role of biologic agents. J Manag Care Pharm. 2004;10(4):318-325.
Gisondi P, Vedove CD, Girolomoni G. Efficacy and Safety of Secukinumab in Chronic Plaque Psoriasis and Psoriatic Arthritis Therapy. Dermatol Ther (Heidelb). 2014;4(1):1-9.
Sanford M, McKeage K. Secukinumab: first global approval. Drugs. 2015;75(3):329-38.
Topal IO, Baysak S, Altunay IK, Polat AK, Arikan EE, Ozkur E, et al. Evaluation of the efficacy, safety, and side effects of secukinumab in patients with moderate-to-severe psoriasis: real-world data from a retrospective multicenter study. An Bras Dermatol. 2022;97(5):566-74.
Alexander A, Navarini MD, Poulin Y, Menter A, Yihua Gu MS, Teixeira HD. Analysis of body region and components of PASI scores during adalimumab or methotrexate treatment for patients with moderate-to-severe psoriasis. J Drugs Dermatol. 2014;13(5):554-62.
Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)—a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19(3):210-16.
Yan Zhao, Lin Cai, Xiao-Yang Liu, Heng Zhang, Jin-Zhong Zhang. Efficacy and safety of secukinumab in Chinese patients with moderate-to-severe plaque psoriasis: a real-life cohort study. Chin Med J (Engl). 2021;134(11):1324-28.
Neema S, Radhakrishnan S, Singh S, Vasudevan B, Chatterjee M. Real-life efficacy and safety of secukinumab: A single-center, retrospective observational study with 52-week follow-up. Indian J Drugs Dermatol. 2019;5(6):14.
Lin Cai, Jian-Zhong Shang, Xu Yao. Secukinumab demonstrates high efficacy and a favorable safety profile over 52 weeks in Chinses patients with moderate to severe plaque psoriasis. Chinese Medical Journal. 2020;133(22):2665.
Tariq H, Basharat M, Javed S, Aman S. Efficacy and safety of secukinumab in treatment of moderate to severe psoriasis. J Pak Assoc Dermatol. 2022;32(1):9-14.
Momose M, Asahina A, Umezawa Y, Nakagawa H. Long-term clinical efficacy and safety of secukinumab for Japanese patients with psoriasis: A single-center experience. J Dermatol. 2018;45(3):318-21.
Rich P, Sigurgeirsson B, Thaci D, Ortonne JP, Paul C, Schopf RE, et al. Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled, phase II regimen-finding study. Br J Dermatol. 2013;168(2):402-11.
Pariser D, Frankel E, Schlessinger J, Poulin Y, Vender R, Langley RG, et al. Efficacy of Secukinumab in the Treatment of Moderate to Severe Plaque Psoriasis in the North American Subgroup of Patients: Pooled Analysis of Four Phase 3 Studies. Dermatol Ther (Heidelb). 2018;8(1):17-32.
Huang W, Na L, Fidel PL, Schwarzenberger P. Requirement of interleukin-17A for systemic anit-Candida albicans host defense in mice. J Infect Dis. 2004;190(3):624-31.
Papp KA, Langley RG, Sigurgeirsson B, Abe M, Baker DR, Konno P. Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study. Br J Dermatol. 2013;168(2):412-421.
